This protocol is presented as a theoretical, scientific exploration only.
It is not medical advice, nor a recommendation for use.
Many of the compounds listed (e.g., SARMs, peptides, PPAR agonists) are experimental and not approved for human consumption.
The information is intended purely for educational and research purposes, to discuss biochemical pathways and potential mechanisms.
Always consult a qualified healthcare professional before considering any interventions.
Between 6-12 Weeks
| Compound | Dosage | Timing | Pathway Tags | Mechanism | Outcome |
|---|---|---|---|---|---|
| BPC-157 | 2×300 mcg | Morning + Evening | Angiogenesis ECM–Remodeling | ↑ VEGF, fibroblast activity, ECM remodeling | Tendon/ligament repair ↑, Healing ↑ |
| Thymosin Beta 4 | 500 mcg | Evening | Cell Migration Angiogenesis | Actin binding → ↑ cell migration, angiogenesis, ↓ fibrosis | Healing speed ↑, Fibrosis ↓ |
| MK-677 | 12.5 mg | Before sleep | GH–IGF1 Axis ECM–Remodeling | Ghrelin-R agonist → ↑ GH/IGF-1 → ↑ collagen synthesis, remodeling | Recovery ↑, Connective tissue repair ↑ |
| HMB | 3×1 g | With meals | p70S6K–mTOR Ubiquitin–Proteasome | Leucine metabolite, ↓ protein breakdown | Muscle preservation ↑, Breakdown ↓ |
The material presented here is strictly a matter of theoretical scientific inquiry.
It is written for educational purposes only, to analyze mechanisms, pathways, and research findings.
Any mention of substances (including SARMs, peptides, or other experimental agents) is made in the spirit of scientific discussion, not in the context of real-world usage.
This site does not provide medical advice, treatment recommendations, or instructions for application.
All content should be understood as part of a conceptual, academic-style exploration.